# Innovent Biologics (Suzhou) Co. Ltd.: Phase 2 study closed enrollment, 203 enrolled (Melanoma)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy |
| NCT ID | NCT06797297 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Melanoma |
| Intervention types | biological |
| Target enrollment | 203 |
| Site countries | China |
| Posted | 2025-01-28 |
| Planned start | 2025-02-24 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 203 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06797297). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.